BIRC5 has been targeted by immunotherapy in a number of ways (recently reviewed in [57]) including through combined treatment with YM155, a novel small molecule transcriptional inhibitor of BIRC5 which when used with chemotherapeutic agents can increase drug efficacy on AML cells [58]. Here, BIRC5 is linked to acute myeloid leukemia.